An anonymous director reports

QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE

Quantum Biopharma Ltd. has provided the following corporate update.

The company has granted an aggregate of 572,500 stock options to certain directors, officers, employees and consultants of the company. Each stock option is exercisable at a price of $4.80 for a period of five years from the date of grant, expiring on Aug. 20, 2031. Of the stock options, 172,500 vested immediately upon grant and the remaining 400,000 stock options are subject to performance-based vesting conditions.

The stock options and the common shares underlying the stock options are subject to a statutory four-month-and-one-day hold period. All stock options were granted in accordance with the company's omnibus equity incentive plan approved by shareholders on June 29, 2023.

About Quantum Biopharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented Unbuzzd and spun out its OTC (over-the-counter) version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48 per cent (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7 per cent of sales from Unbuzzd until payments to Quantum total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

We seek Safe Harbor.